Contact Us
Reviews
Treatments
Our Location
At H3O Wellness in Twin Falls, ID, we understand how exhausting and frustrating it can be to try treatment after treatment without relief. If you’ve been living with treatment-resistant depression, there is hope.
Spravato® (esketamine) offers a groundbreaking alternative designed to work differently than traditional antidepressants. Backed by science and administered in a safe, supportive environment, Spravato may be the path forward you’ve been searching for.
SPRAVATO® is an innovative treatment for individuals living with treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal ideation.
SPRAVATO® (esketamine) is an FDA-approved nasal spray that works differently from traditional antidepressants, providing relief for patients who have not responded to other treatments. Administered under medical supervision, SPRAVATO® is used in conjunction with an oral antidepressant to help improve symptoms and support long-term mental health stability.
SPRAVATO® targets the NMDA receptors in the brain, influencing glutamate production, which plays a key role in mood regulation and neural connectivity.
This mechanism allows for rapid symptom relief, often within hours or days, compared to traditional antidepressants that may take weeks to take effect. The treatment is administered as a nasal spray in a controlled clinical setting, ensuring patient safety and effectiveness.
SPRAVATO® is FDA-approved for the treatment of:
Before starting SPRAVATO® therapy at H3O Wellness, patients undergo a thorough medical evaluation to determine eligibility. Each treatment session includes:
H3O Wellness provides a safe and structured environment for SPRAVATO® therapy, ensuring that each patient receives personalized care from experienced medical providers.
Our team is committed to supporting individuals with treatment-resistant depression, offering evidence-based treatments in a compassionate and professional setting.
Each session lasts approximately two hours, including the post-administration observation period.
The initial treatment plan includes twice-weekly sessions for the first month, followed by a tapering schedule based on individual response.
No. Patients must arrange for transportation home, as driving is not permitted until the day after treatment.
Some patients experience improvement in symptoms within hours or days, while others may need multiple sessions for full therapeutic effect.
